Original Article
Increased Prevalence of Skeletal Anomalies on Ultrasound Evaluation of Buprenorphine-Exposed Human Fetuses
Abstract
Objectives: In this study, buprenorphine was the primary source of maternal opioid exposure at the time of initial prenatal evaluation. Current recommendations advise that level II ultrasounds be performed in patients with substance use disorders. For some patients, distance, transportation, and costs associated with obtaining ultrasounds from a specialist pose significant barriers. This study was thus undertaken to evaluate the value of level II ultrasounds in buprenorphine-exposed pregnancies.Methods: In a retrospective chart review comparing 1188 substance-exposed patients with 1261 nonexposed, anomaly data were collected from level I and level II anatomy scans, problem lists on prenatal flowsheets, and visit notes. If anomalies were detected, then they were further classified by the affected organ system. Two proportion tests were used to compare the exposed and unexposed groups. When the assumptions were not met, a Fisher exact test and the Benjamini-Hochberg method were used to adjust for multiple testing.
Results: Buprenorphine-exposed fetuses have increased rates of composite skeletal anomalies when compared with nonexposed fetuses (P< 0.005). No statistically significant difference, however, was found between groups for any other system or for any specific skeletal anomaly. No statistical difference was found related to buprenorphine dose.
Conclusions: This is the first report of skeletal anomalies in buprenorphine-exposed human fetuses. Causality is unproven, but this report is consistent with prior human and animal studies in which maternal opioid use has been linked to significant impairments in bone growth and development. Our findings suggest that anatomic surveys of fetuses exposed to buprenorphine should be performed by individuals with expertise in the detection of fetal skeletal anomalies.
Posted in: Pregnancy34
This content is limited to qualifying members.
Existing members, please login first
If you have an existing account please login now to access this article or view purchase options.
Purchase only this article ($25)
Create a free account, then purchase this article to download or access it online for 24 hours.
Purchase an SMJ online subscription ($75)
Create a free account, then purchase a subscription to get complete access to all articles for a full year.
Purchase a membership plan (fees vary)
Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.
References
1. Alexander C, Breuel K, Olsen M. High prevalence of buprenorphine in prenatal drug screens in an Appalachian city. South Med J 2020;113:111-115.
2. Prince MK, Daley SF, Ayers D. Substance use in pregnancy. In: StatPearls. Treasure Island, FL: StatPearls Publishing; 2023.
3. AIUM Practice Parameter for the performance of detailed second- and third-trimester diagnostic obstetric ultrasound examinations. J Ultrasound Med 2019;38:3093-3100.
4. Yen E, Davis JM. The immediate and long-term effects of prenatal opioid exposure. Front Pediatr 2022;10:1039055.
5. MacMillan KDL. Neonatal abstinence syndrome: review of epidemiology, care models, and current understanding of outcomes. Clin Perinatol 2019;46:817-832.
6. Fill MA, Miller AM, Wilkinson RH, et al. Educational disabilities among children born with neonatal abstinence syndrome. Pediatrics 2018;142:e20180562.
7. Broussard CS, Rasmussen SA, Reefhuis J, et al. Maternal treatment with opioid analgesics and risk for birth defects. Am J Obstet Gynecol 2011;204:314.e1-314.e11.
8. Dickson SA, Mazza DP, Waddell ML, et al. In utero effects of opioids on fetal growth. J Matern Fetal Neonatal Med 2023;36:2238239.
9. Källén B, Borg N, Reis M. The use of central nervous system active drugs during pregnancy. Pharmaceuticals (Basel) 2013;6:1221-1286.
10. Wen X, Belviso N, Murray E, et al. Association of gestational opioid exposure and risk of major and minor congenital malformations. JAMA Netw Open 2021;4:e215708.
11. Shaw GM, Malcoe LH, Swan SH, et al. Congenital cardiac anomalies relative to selected maternal exposures and conditions during early pregnancy. Eur J Epidemiol 1992;8:757-760.
12. Nezvalová-Henriksen K, Spigset O, Nordeng H. Effects of codeine on pregnancy outcome: results from a large population-based cohort study. Eur J Clin Pharmacol 2011;67: 1253-1261.
13. Bateman BT, Hernandez-Diaz S, Straub L, et al. Association of first trimester prescription opioid use with congenital malformations in the offspring: population based cohort study. BMJ 2021;372:n102.
14. Indivior PLC. Highlights of prescribing information—Suboxone. https://www.suboxone.com/pdfs/prescribing-information.pdf. Accessed March 8, 2024.
15. Saeidinezhad M, Razban V, Safizadeh H, et al. Effects of maternal consumption of morphine on rat skeletal system development. BMC Musculoskelet Disord 2021;22:435.
16. Schramm T, Mommsen H. Fetal skeletal disorders. Ultraschall Med 2018;39:610-634.
17. American College of Obstetricians and Gynecologists’ Committee on Obstetric Practice. Opioid use and opioid use disorder in pregnancy. Obstet Gynecol 2017;130: e81–e94.
18. Kanervo MM, Tupola SJ, Nikkola EM, et al. Buprenorphine-naloxone, buprenorphine, and methadone throughout pregnancy in maternal opioid use disorder. Acta Obstet Gynecol Scand 2023;102:313-322.
19. Rodriguez CE, Klie KA. Pharmacological treatment of opioid use disorder in pregnancy. Semin Perinatol 2019;43:141-148.
20. Suarez EA, Huybrechts KF, Straub L, et al. Buprenorphine versus methadone for opioid use disorder in pregnancy. N Engl J Med 2022;387:2033-2044.
21. Suarez EA, Bateman BT, Straub L, et al. First trimester use of buprenorphine or methadone and the risk of congenital malformations. JAMA Intern Med 2024;184:242-251.
22. Winkelman TNA, Villapiano N, Kozhimannil KB, et al. Incidence and costs of neonatal abstinence syndrome among infants with Medicaid: 2004-2014. Pediatrics 2018;141: e20173520.
23. Patrick SW, Davis MM, Lehmann CU, et al. Increasing incidence and geographic distribution of neonatal abstinence syndrome: United States 2009 to 2012. J Perinatol 2015;35:650-655.
24. Kushnir A, Bhavsar R, HannaE, et al. Neonatal abstinence syndrome in infants with prenatal exposure to methadone versus buprenorphine. Children (Basel) 2023;10:1030.
25. Ryan KS, Prewitt KC, Hayer S, et al. Opioid use in pregnancy: a review. Obstet Gynecol Surv 2023;78:35-49.
26. Shore S, Lewis N, Olsen M. Rise in neonatal abstinence syndrome rate is associated with increase in buprenorphine prescription numbers. South Med J 2023;116:930-937.
27. Bierce L, Tabachnick AR, Eiden RD, et al. A 12-month follow-up of infant neurodevelopmental outcomes of prenatal opioid exposure and polysubstance use. Neurotoxicol Teratol 2023;97:107176.
28. Kaltenbach K, Finnegan LP. Developmental outcome of children born to methadone maintained women: a review of longitudinal studies. Neurobehav Toxicol Teratol 1984;6: 271-275.
29. Kaltenbach KA, Finnegan LP. Studies of prenatal drug exposure and environmental research issues: the benefits of integrating research within a treatment program. NIDA Res Monogr 1992;117:259-270.
30. Andersen JM, Høiseth G, Nygaard E. Prenatal exposure to methadone or buprenorphine and long-term outcomes: a meta-analysis. Early Hum Dev 2020;143:104997.
31. Anbalagan S, Falkowitz DM, Mendez MD. Neonatal abstinence syndrome. In: StatPearls. Treasure Island, FL: StatPearls Publishing; 2024.
32. Nelson LF, Yocum VK, Patel KD, et al. Cognitive outcomes of young children after prenatal exposure to medications for opioid use disorder: a systematic review and meta-analysis. JAMA Netw Open 2020;3:e201195.
33. Yeoh SL, Eastwood J, Wright IM, et al. Cognitive and motor outcomes of children with prenatal opioid exposure: a systematic review and meta-analysis. JAMA Netw Open 2019;2:e197025.
34. Towers CV, Hyatt BW, Visconti KC, et al. Neonatal head circumference in newborns with neonatal abstinence syndrome. Pediatrics 2019;143:e20180541.
35. Caritis SN, Panigrahy A. Opioids affect the fetal brain: reframing the detoxification debate. Am J Obstet Gynecol 2019;221:602-608.
36. Kortekaas JC, Kazemier BM, Keulen JKJ, et al. Risk of adverse pregnancy outcomes of late- and postterm pregnancies in advanced maternal age: a national cohort study. Acta Obstet Gynecol Scand 2020;99:1022-1030.
37. Alexander C, Olsen M.1023:acomparisonofBMI and drug screens among pregnant patients at an Appalachian clinic. Am J Obstet Gynecol 2020;222:S635-S636.
38. Persson M, RazazN, Edstedt Bonamy AK, etal. Maternal overweight and obesity and risk of congenital heart defects. J Am Coll Cardiol 2019;73:44-53.
39. Wu XX, Ge RX, Huang L, et al. Pregestational diabetes mediates the association between maternal obesity and the risk of congenital heart defects. J Diabetes Investig 2022;13:367-374.
40. Sadler TW. Langman’s Medical Embryology, 15th ed. Baltimore, MD: Wolters Kluwer; 2024.
41. Breeland G, Sinkler MA, Menezes RG. Embryology, bone ossification. In: StatPearls. Treasure Island, FL: StatPearls Publishing; 2023.
42. Hall SM, Prochaska JJ. Treatment of smokers with co-occurring disorders: emphasis on integration in mental health and addiction treatment settings. Ann Rev Clin Psychol 2009;5:409–431.
43. Weinberger AH, Platt J, Esan H, et al. Cigarette smoking is associated with increased Risk of substance use disorder relapse: a nationally representative, prospective longitudinal investigation. J Clin Psychiatry 2017;78:E152–E160.
44. Hackshaw A, Rodeck C, Boniface S. Maternal smoking in pregnancy and birth defects: a systematic review based on 173 687 malformed cases and 11.7 million controls. Hum Reprod Update 2011;17:589–604.
45. Raitio A, Heiskanen S, Syvänen J, et al. Maternal risk factors for congenital vertebral anomalies. JBoneJointSurg2023;105:1087–1092.
46. Yang L, Wang H, Yang L, et al. Maternal cigarette smoking before or during pregnancy increases the risk of birth congenital anomalies: a population-based retrospective cohort study of 12 million mother-infant pairs. BMC Med 2022;20:4.
